Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy.

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder affecting peripheral nerves.
• Immunomodulatory therapies are increasingly explored for neuromuscular diseases.
• Mycophenolate mofetil (MMF) is an established immunosuppressant with potential in autoimmune conditions.

Observation:

• A retrospective analysis of 184 CIDP patients identified eight who received MMF therapy.
• Patients received a mean MMF dose of 2 g/day for a median of 15.2 months.
• Clinical, laboratory, and electrophysiological data were collected.

Findings:

• MMF therapy led to a significant reduction in the average Neuropathy Impairment Score (p<0.001).
• Six out of eight patients were able to reduce or discontinue other CIDP treatments, including corticosteroids and intravenous immunoglobulin.
• The mean Neuropathy Impairment Score decreased from 72.3 to 37.8.

Implications:

• MMF demonstrates potential as an effective treatment for both new and treatment-resistant CIDP.
• These pilot findings support the need for larger, controlled clinical trials to confirm MMF's efficacy in CIDP.
• MMF may offer a valuable therapeutic option for managing CIDP, potentially improving patient outcomes and reducing reliance on other medications.